Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (NGENF)
OTHER OTC:NGENF
NervGen Pharma (NGENF) Stock Price & Analysis
38 Followers
NGENF Stock Chart & Stats
Day’s Range$1.45 - $1.64
52-Week Range― - ―
Previous Close$1.5
Volume34.43K
Average Volume (3M)N/A
Market Cap
$89.69M
Enterprise Value$79.03M
Total Cash (Recent Filing)C$14.79M
Total Debt (Recent Filing)C$219.24K
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NervGen Pharma News
PremiumCompany Announcements
NervGen Advances Spinal Injury Drug, Secures Funds
PremiumCompany Announcements
NervGen Secures $23M for Drug DevelopmentOptions Prices
Currently, No data available
---
Ownership Overview
31.37% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
68.62% Public Companies and
Individual Investors
NGENF FAQ
What was NervGen Pharma’s price range in the past 12 months?
Currently, no data Available
What is NervGen Pharma’s market cap?
Currently, no data Available
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is May 01, 2024 which is in 12 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Nov 09, 2023. The company reported -$0.051 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.051.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Overvalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NervGen Pharma have?
Currently, no data Available
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -$0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.451%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGENF
---
NervGen Pharma Stock Smart Score
Company Description
NervGen Pharma
NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
---
Technical Analysis
---